Tarlatamab demonstrates ‘remarkable’ duration of response in SCLC
Click Here to Manage Email Alerts
AMG 757, or tarlatamab, demonstrated safety and efficacy among patients with small cell lung cancer, according to updated phase 1 data presented at the virtual ASCO annual meeting.
The agent is a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy that targets DLL3, an inhibitory Notch ligand, because it is “highly expressed” in patients with small cell lung cancer (SCLC). Preliminary results, which included the first nine dosing cohorts, indicated efficacy of tarlatamab (Amgen), according to the abstract.
Taofeek K. Owonikoko, MD, PhD, MS, professor and vice-chair for faculty development in the department of hematology and medical oncology at Emory University School of Medicine and co-leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University, and colleagues presented updated safety, efficacy, and pharmacokinetic findings that used data from 10 patient cohorts.
The study included patients with SCLC at 10 dose levels (0.003-100mg) of tarlatamab. Therapy was administered every 2 weeks via IV.
According to the abstract, median treatment duration was 6 weeks and 83% of patients experienced treatment-related adverse events. Of these adverse events, 25% were grade 3, 6% were grade 4 and 2% were grade 5 with only one leading to discontinuation of the study.
In the final efficacy analyses, the researchers included 60 patients who were treated across 10 dose levels over a median follow-up of 4.2 weeks. Partial response was confirmed for 13% of patients, while 63% achieved unconfirmed partial response at the final dose level (100mg).
“For responding patients, the durability of response is remarkable,” Owonikoko said during a presentation. “In the 13 patients with confirmed partial response, median duration of response was measured at 8.7 months. Patients responded very quickly to treatment with median time to response of 1.8 months.”
The study is ongoing and the investigators expected to present more updated data concerning response rates and duration of response.
Collapse
Owonikoko TK, et al. Abstract 8510. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Click Here to Manage Email Alerts